Dr. Sohi on the timing of PSMA-PET imaging in prostate cancer

EP: 1.Harnessing the Full Power of PSMA-PET Requires Multidisciplinary Approach

EP: 2.Dr. Spratt on the importance of a multidisciplinary approach to PSMA-PET

EP: 3.PSMA-PET leads imaging breakthroughs in prostate cancer paradigm

EP: 4.Conventional imaging obstacles that PSMA-PET overcomes

Now Viewing

EP: 5.Dr. Sohi on the timing of PSMA-PET imaging in prostate cancer

EP: 6.Dr. Sohi on why PSMA-PET results can alter treatment plans

In this video, Jaideep S. Sohi, MD, explains factors to consider regarding the timing of re-imaging with PSMA-PET in patients with prostate cancer. Sohi is a nuclear medicine physician with Northwestern University and American Molecular Imaging.

Transcription

We always want to know, “Okay, we've had one baseline [scan,] so when do we scan the patient next?” And it depends on multiple factors. Most importantly, it's going to be the patient's clinical condition. So after therapy, you assess how the patient is doing. Are they having any new clinical symptoms that can raise concern for the possibility of metastatic or recurrent disease? Most commonly, the patient followed by their PSA level and the urologist and/or the treating physician will evaluate the PSA and the patient’s clinical status and then make a decision on when they feel is appropriate to re-image the patient with PSMA-PET. Typically, this happens in patients who have what we call biochemical recurrence, which is a rising PSA after prostatectomy or radiation therapy.

Transcription has been edited for clarity.